Dgci

• 

  After Pharma Firm's Huge Eye Drop Claim, Regulator Withdraws Permission

  Taking serious note of Mumbai-based Entod Pharmaceuticals' claims that it can help reduce dependency on reading glasses for those suffering from presbyopia, the Drugs Controller General of India (DGCI) has suspended permission given to the company.

• 

  Cryptocurrency Exchanges Across India Said to Face DGCI Crackdown, Rs. 70-Crore Tax Evasion Detected

  After the massive tax evasion of GST by Cryptocurrency Service providers WazirX, the Directorate General of GST Intelligence has come down heavily on Cryptocurrency exchanges operating in the country, said sources.

• 

  Foreign Vaccines Like Pfizer, Moderna A Step Closer With Key India Waiver

  In a big move to clear the way for foreign vaccines like Pfizer and Moderna, the drug regulator has done away with the requirement of India-specific trials.

• 

  Zydus Cadila's "Virafin" Approved For Treating Moderate Covid Cases

  The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, "Virafin" for treating moderate COVID-19 infection in adults.

• 

  Covid Vaccines Being "Analysed Aggressively", Says Minister Amid Key Meet

  Applications for the emergency use approval for the coronavirus vaccines filed by the Serum Institute of India, Bharat Biotech and Pfizer are being taken up once again for consideration by a government-appointed panel of experts today.

• 

  Ready To Restart: Indian Drug Firm After UK Covid Vaccine Trials Resume

  The Serum Institute of India (SII) is ready to restart coronavirus vaccine trials - pending permission from the Drug Controller General of India (DGCI) - the manufacturer said in a statement on Saturday evening

• 

  Central Drug Agency Warns Of Black Marketing Of COVID-19 Drug Remdesivir

  The Drug Controller General of India (DGCI) has raised concerns over black marketing and profiteering of Remdesivir, an antiviral drug prescribed for treatment of suspected or severe lab-confirmed cases of COVID-19.

• 

  Research Body CSIR To Begin Two Drug Trials For COVID-19

  The Council for Scientific and Industrial Research (CSIR) has received approval from Drug Controller General of India (DGCI) for its two clinical trial drugs - ''favipiravir'' and ''phytopharmaceutical'' - to combat coronavirus.

• Natco Pharma Gains on Receiving Drug Approval From India

  Natco Pharma said that it is the first company in India to receive approval for generic sofosbuvir 400 mg tablets from DGCI which is used for treatment of chronic hepatitis C infection.

• Hospitals, chemists to wait for regulatory word on Ranbaxy

  The Drug Controller General of India (DGCI) DGCI is conducting a "focussed scrutiny" of medicines sold by Ranbaxy and some other drug makers. The drug regulator has, however, said that it remains confident of the quality standards of Indian medicines despite concerns raised by US authorities over some of Ranbaxy's products.

• Biocon gets approval to market anti-psoriasis drug

  Biotechnology major Biocon today said it has received approval from Drug Controller General of India (DCGI) to market its product 'Itolizumab', used in the treatment of psoriasis.

• Glenmark gets DCGI nod for phase III trials of diarrhoea drug

  Napo Pharmaceuticals Inc, however, had recently claimed terminating an agreement signed in July 2005 with Glenmark regarding Crofelemer.